Concepts (118)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Piperazines | 3 | 2008 | 86 | 0.300 |
Why?
|
| bcl-2-Associated X Protein | 1 | 2007 | 48 | 0.270 |
Why?
|
| Apoptosis | 5 | 2013 | 1096 | 0.240 |
Why?
|
| Cancer Vaccines | 2 | 2018 | 51 | 0.230 |
Why?
|
| Leukemia, Myeloid, Acute | 1 | 2007 | 191 | 0.230 |
Why?
|
| Lipoma | 1 | 2025 | 17 | 0.220 |
Why?
|
| Ankle | 1 | 2025 | 28 | 0.220 |
Why?
|
| CD8-Positive T-Lymphocytes | 3 | 2018 | 664 | 0.190 |
Why?
|
| Antigen Presentation | 2 | 2018 | 240 | 0.140 |
Why?
|
| Melanoma, Experimental | 2 | 2014 | 42 | 0.120 |
Why?
|
| Cell Line, Tumor | 5 | 2018 | 1566 | 0.120 |
Why?
|
| Toll-Like Receptor 8 | 1 | 2014 | 50 | 0.110 |
Why?
|
| Peptides | 1 | 2018 | 596 | 0.100 |
Why?
|
| Aurora Kinases | 3 | 2008 | 12 | 0.100 |
Why?
|
| Toll-Like Receptor 7 | 1 | 2014 | 104 | 0.100 |
Why?
|
| Adaptive Immunity | 1 | 2014 | 105 | 0.100 |
Why?
|
| Cyclopropanes | 3 | 2008 | 55 | 0.100 |
Why?
|
| Pyrazoles | 3 | 2008 | 88 | 0.100 |
Why?
|
| Pyrimidines | 3 | 2008 | 146 | 0.100 |
Why?
|
| Neoplasm Staging | 2 | 2010 | 536 | 0.090 |
Why?
|
| Nasopharyngeal Neoplasms | 2 | 2010 | 51 | 0.090 |
Why?
|
| Melanoma | 1 | 2014 | 332 | 0.080 |
Why?
|
| Chemokine CXCL12 | 1 | 2009 | 27 | 0.080 |
Why?
|
| Antibodies, Neutralizing | 1 | 2010 | 218 | 0.070 |
Why?
|
| Neovascularization, Physiologic | 1 | 2009 | 112 | 0.070 |
Why?
|
| Antibodies, Viral | 1 | 2010 | 326 | 0.070 |
Why?
|
| Immunity, Innate | 1 | 2014 | 828 | 0.070 |
Why?
|
| Epithelium | 1 | 2008 | 100 | 0.070 |
Why?
|
| Mesoderm | 1 | 2008 | 88 | 0.070 |
Why?
|
| Etoposide | 1 | 2007 | 33 | 0.070 |
Why?
|
| fms-Like Tyrosine Kinase 3 | 1 | 2007 | 24 | 0.070 |
Why?
|
| G2 Phase | 1 | 2007 | 23 | 0.070 |
Why?
|
| Drug Screening Assays, Antitumor | 1 | 2007 | 43 | 0.070 |
Why?
|
| Endothelial Cells | 1 | 2009 | 205 | 0.070 |
Why?
|
| Drug Synergism | 1 | 2007 | 143 | 0.070 |
Why?
|
| Vascular Endothelial Growth Factor A | 1 | 2009 | 232 | 0.070 |
Why?
|
| Laryngeal Neoplasms | 1 | 2007 | 49 | 0.070 |
Why?
|
| Radiation Tolerance | 1 | 2007 | 56 | 0.070 |
Why?
|
| Ischemia | 1 | 2009 | 203 | 0.070 |
Why?
|
| Mitogen-Activated Protein Kinases | 1 | 2008 | 213 | 0.060 |
Why?
|
| Bone Marrow Cells | 1 | 2007 | 240 | 0.060 |
Why?
|
| Enzyme Activation | 1 | 2007 | 389 | 0.060 |
Why?
|
| Caspases | 1 | 2007 | 177 | 0.060 |
Why?
|
| Cell Division | 1 | 2007 | 449 | 0.060 |
Why?
|
| Carcinoma, Squamous Cell | 1 | 2007 | 261 | 0.060 |
Why?
|
| Muscle, Skeletal | 1 | 2009 | 766 | 0.050 |
Why?
|
| Antineoplastic Agents | 1 | 2007 | 649 | 0.050 |
Why?
|
| Genetic Therapy | 1 | 2009 | 836 | 0.040 |
Why?
|
| Diagnosis, Differential | 1 | 2025 | 992 | 0.040 |
Why?
|
| Mice | 4 | 2018 | 11132 | 0.040 |
Why?
|
| Male | 4 | 2025 | 30926 | 0.040 |
Why?
|
| Mutation | 1 | 2007 | 2679 | 0.040 |
Why?
|
| Female | 4 | 2025 | 33874 | 0.040 |
Why?
|
| Mice, Inbred C57BL | 2 | 2018 | 3474 | 0.030 |
Why?
|
| Vaccines, Subunit | 1 | 2018 | 40 | 0.030 |
Why?
|
| Child | 1 | 2007 | 4629 | 0.030 |
Why?
|
| Tyrosine | 1 | 2018 | 94 | 0.030 |
Why?
|
| Adolescent | 1 | 2007 | 6311 | 0.030 |
Why?
|
| Middle Aged | 3 | 2010 | 18172 | 0.030 |
Why?
|
| Adjuvants, Immunologic | 1 | 2018 | 235 | 0.030 |
Why?
|
| Cell Movement | 2 | 2009 | 476 | 0.030 |
Why?
|
| Humans | 6 | 2025 | 64976 | 0.030 |
Why?
|
| Animals | 4 | 2018 | 21408 | 0.030 |
Why?
|
| Magnetic Resonance Imaging | 1 | 2025 | 2244 | 0.030 |
Why?
|
| Vaccination | 1 | 2018 | 375 | 0.030 |
Why?
|
| Dendritic Cells | 1 | 2018 | 533 | 0.030 |
Why?
|
| Injections, Intralesional | 1 | 2014 | 14 | 0.030 |
Why?
|
| CTLA-4 Antigen | 1 | 2014 | 73 | 0.030 |
Why?
|
| Lymphocytes, Tumor-Infiltrating | 1 | 2014 | 40 | 0.030 |
Why?
|
| Chemokine CCL2 | 1 | 2014 | 61 | 0.030 |
Why?
|
| Tumor Burden | 1 | 2014 | 76 | 0.030 |
Why?
|
| Prognosis | 2 | 2010 | 1780 | 0.030 |
Why?
|
| Imidazoles | 1 | 2014 | 81 | 0.030 |
Why?
|
| Inflammasomes | 1 | 2018 | 347 | 0.030 |
Why?
|
| Cytotoxicity, Immunologic | 1 | 2014 | 140 | 0.030 |
Why?
|
| Leukocytes | 1 | 2014 | 105 | 0.030 |
Why?
|
| Nitric Oxide | 1 | 2014 | 164 | 0.030 |
Why?
|
| Fas Ligand Protein | 1 | 2013 | 40 | 0.020 |
Why?
|
| Aged | 1 | 2007 | 14881 | 0.020 |
Why?
|
| RNA, Small Interfering | 2 | 2008 | 970 | 0.020 |
Why?
|
| Interferon-gamma | 1 | 2013 | 575 | 0.020 |
Why?
|
| Deoxyribonucleases | 1 | 2010 | 32 | 0.020 |
Why?
|
| Phenotype | 1 | 2014 | 1242 | 0.020 |
Why?
|
| Adult | 1 | 2007 | 17273 | 0.020 |
Why?
|
| Disease-Free Survival | 1 | 2010 | 246 | 0.020 |
Why?
|
| Antigens, Viral | 1 | 2010 | 131 | 0.020 |
Why?
|
| Antibodies, Monoclonal | 1 | 2014 | 879 | 0.020 |
Why?
|
| ROC Curve | 1 | 2010 | 292 | 0.020 |
Why?
|
| Carcinoma | 1 | 2010 | 130 | 0.020 |
Why?
|
| Laser-Doppler Flowmetry | 1 | 2009 | 7 | 0.020 |
Why?
|
| Kaplan-Meier Estimate | 1 | 2010 | 419 | 0.020 |
Why?
|
| Injections, Intramuscular | 1 | 2009 | 71 | 0.020 |
Why?
|
| Epstein-Barr Virus Infections | 1 | 2010 | 104 | 0.020 |
Why?
|
| Hindlimb | 1 | 2009 | 54 | 0.020 |
Why?
|
| Retroviridae | 1 | 2009 | 75 | 0.020 |
Why?
|
| Stem Cell Transplantation | 1 | 2009 | 80 | 0.020 |
Why?
|
| Regional Blood Flow | 1 | 2009 | 116 | 0.020 |
Why?
|
| Herpesvirus 4, Human | 1 | 2010 | 198 | 0.020 |
Why?
|
| Mice, Nude | 1 | 2009 | 287 | 0.020 |
Why?
|
| Butadienes | 1 | 2008 | 14 | 0.020 |
Why?
|
| Combined Modality Therapy | 1 | 2009 | 371 | 0.020 |
Why?
|
| Nitriles | 1 | 2008 | 84 | 0.020 |
Why?
|
| beta Catenin | 1 | 2008 | 99 | 0.020 |
Why?
|
| Cadherins | 1 | 2008 | 90 | 0.020 |
Why?
|
| Transduction, Genetic | 1 | 2009 | 245 | 0.020 |
Why?
|
| Mice, Inbred BALB C | 1 | 2009 | 875 | 0.020 |
Why?
|
| Neoplasm Invasiveness | 1 | 2008 | 286 | 0.020 |
Why?
|
| Down-Regulation | 1 | 2008 | 325 | 0.020 |
Why?
|
| MAP Kinase Signaling System | 1 | 2008 | 235 | 0.020 |
Why?
|
| Proto-Oncogene Proteins c-akt | 1 | 2007 | 214 | 0.020 |
Why?
|
| Phosphorylation | 1 | 2008 | 970 | 0.010 |
Why?
|
| Tumor Suppressor Protein p53 | 1 | 2007 | 313 | 0.010 |
Why?
|
| Survival Rate | 1 | 2007 | 850 | 0.010 |
Why?
|
| Cells, Cultured | 1 | 2009 | 2197 | 0.010 |
Why?
|
| Cell Differentiation | 1 | 2009 | 1386 | 0.010 |
Why?
|
| Genetic Vectors | 1 | 2009 | 917 | 0.010 |
Why?
|
| Disease Models, Animal | 1 | 2009 | 2289 | 0.010 |
Why?
|
| Time Factors | 1 | 2009 | 3759 | 0.010 |
Why?
|